Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20562997 | 0.84 | HTR1D (0.35) | — | |
| SCHEMBL23783240 | 0.80 | TAAR1 (0.35) | L3MBTL1TAAR1 | |
| SCHEMBL2076815 | 0.78 | CNR1 (0.33) | L3MBTL1TAAR1 | |
| SCHEMBL20561727 | 0.77 | LMNA (0.34) | L3MBTL1 | |
| SCHEMBL91980 | 0.76 | DGAT1 (0.31) | DGAT1GPR17TAAR1 | |
| SCHEMBL31722228 | 0.76 | TSHR (0.37) | L3MBTL1TAAR1 | |
| SCHEMBL601770 | 0.76 | DGAT1 (0.31) | DGAT1GPR17TAAR1 | |
| SCHEMBL856734 | 0.74 | TAAR1 (0.39) | DGAT1GPR17TAAR1 | |
| SCHEMBL146843 | 0.74 | DGAT1 (0.30) | DGAT1GPR17TAAR1 | |
| SCHEMBL378361 | 0.74 | TAAR1 (0.34) | DGAT1GPR17TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8268946-A | — | — | None | — | — | JP | disclosed |
| WO-2025096495-A1 | ARYL FLUOROSULFATE-BASED INHIBITORS AS NOVEL ANTITUBERCULAR AGENTS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20220041606-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | UNIV VANDERBILT (US) | 2022-02-10 | — | — | US | disclosed |
| EP-3154634-B1 | IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE | UNIV LILLE (FR) | 2021-02-24 | — | — | EP | disclosed |
| US-10323016-B2 | Imidazol- or 1,2,4-triazol-derivatives and their use | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2019-06-18 | — | — | US | disclosed |
| US-10144746-B2 | Bridged bicyclic kallikrein inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20180194780-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9815853-B2 | Bridged bicyclic kallikrein inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170190687-A1 | IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE | Université de Lille (FR) | 2017-07-06 | — | — | US | disclosed |
| EP-3154634-A1 | IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE | Université de Lille 2 Droit et Santé (FR) | 2017-04-19 | — | — | EP | disclosed |
| US-20160362427-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2016-12-15 | — | — | US | disclosed |
| WO-2016201052-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20160102090-A1 | SUBSTITUTED 3-BENZYLQUINOXALIN-4(3H)-ONE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160102090-A1 | SUBSTITUTED 3-BENZYLQUINOXALIN-4(3H)-ONE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160075690-A1 | SUBSTITUTED 1-BENZYLQUINOXALIN-2(1H) ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-17 | — | — | US | disclosed |
| WO-2015189330-A1 | IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2015-12-17 | — | — | WO | disclosed |
| WO-2014179226-A1 | SUBSTITUTED 1-BENZYLQUINOXALIN-2 (1H)-ONE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179237-A1 | SUBSTITUTED 3-BENZYLQUINOXALIN-4(3H)-ONE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY (US) | 2014-11-06 | — | — | WO | disclosed |
| US-5705095-A | LOW VISCOSITY, HIGH DIELECTRIC ANISOTROPY, LIQUID CRYSTALS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-01-06 | — | — | US | disclosed |
| JP-H08268946-A | PARTIALLY FLUORINATED BENZENE DERIVATIVE | MERCK PATENT GMBH | 1996-10-15 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075690-A1 | SUBSTITUTED 1-BENZYLQUINOXALIN-2(1H) ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM2, CHRM5 | DGAT1 2351/4885GPR17 425/4885L3MBTL1 2297/4885 |
| US-10144746-B2 | Bridged bicyclic kallikrein inhibitors | KLKB1, KLK1, KLK2 | DGAT1 2350/4885GPR17 1093/4885L3MBTL1 4262/4885 |
| US-20160362427-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK2 | DGAT1 2350/4885GPR17 1093/4885L3MBTL1 4262/4885 |
| US-20220041606-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM4, CHRM2 | DGAT1 3153/4885GPR17 202/4885L3MBTL1 1764/4885 |
| US-20180194780-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK2 | DGAT1 2350/4885GPR17 1093/4885L3MBTL1 4262/4885 |
| US-20170190687-A1 | IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE | CYP3A43, CYP51A1, CYP3A7 | DGAT1 3057/4885GPR17 2633/4885L3MBTL1 4692/4885 |
| US-20160102090-A1 | SUBSTITUTED 3-BENZYLQUINOXALIN-4(3H)-ONE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYCHOLINE RECEPTOR M1 | CHRM1, CHRM3, CHRM4 | DGAT1 2480/4885GPR17 374/4885L3MBTL1 2067/4885 |
| US-10323016-B2 | Imidazol- or 1,2,4-triazol-derivatives and their use | CYP3A43, CYP51A1, CYP3A7 | DGAT1 3057/4885GPR17 2633/4885L3MBTL1 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.